Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.
Steven N. Seyedin(University of California, San Francisco), Nataliya Mar(University of California, Irvine), Cindy Jiang(The University of Texas MD Anderson Cancer Center), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Dimitrios Stefanoudakis(APLA Health), Amanda Macaraeg(University of California, Irvine), Suzanne M. Dufault(University of California, San Francisco), Terence W. Friedlander(University of California, San Francisco), Mamta Parikh(UC Davis Comprehensive Cancer Center), M. Semaan(University of California, San Francisco), Alexandra Drakaki(UCLA Health), Zachariah Thomas(The University of Texas MD Anderson Cancer Center), Neda Hashemi-Sadraei(University of New Mexico), Kevin R. Reyes(University of California, San Francisco), Omar Alhalabi(The University of Texas MD Anderson Cancer Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Ali Raad(Cancer Clinic)
Cited by 0
Related Papers
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
|JAMA Oncology|2021|185
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|184
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer
|International Journal of Cancer|2013|127